Based on the analysis of its November 2013 meeting, there were no real references to conditions in the economic or pricing sections of the PBAC's Public Summary Documents. At the November 2024 meeting, there were 160. …
The PBAC's 'conditionality' and 'provisional' revolution from 2013 to 2024
August 21, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Australians want more from healthcare as convenience, prevention and fragmentation reshape care
June 18, 2026 - - Latest News -
Life sciences leaders brace for class action wave as dispute risks multiply
June 18, 2026 - - Latest News -
Is China's international benchmarking a bigger short-term risk to medicines access?
June 18, 2026 - - Latest News -
Neurizon secures GMP supply of monepantel to strengthen NUZ 001 commercial readiness
June 17, 2026 - - Australian Biotech -
Percheron completes HMBD-002 drug substance manufacture
June 17, 2026 - - Australian Biotech -
Racura completes significant fund raise to advance three clinical trials
June 17, 2026 - - Australian Biotech -
Novartis names interim leader for Australia and NZ after Country President departs
June 17, 2026 - - Latest News